Download PDF
Z Gastroenterol 2010; 48(2): 258-263
DOI: 10.1055/s-0028-1109782
Kasuistik

© Georg Thieme Verlag KG Stuttgart · New York

Fulminant Hepatic Failure due to Chemotherapy-Induced Hepatitis B Reactivation: Role of Rituximab

Fulminantes Leberversagen bei Chemotherapie-induzierter Hepatitis-B-Reaktivierung: die Rolle von RituximabM. A. Stange1 , O. Tutarel2 , S. Pischke1 , A. Schneider1 , C. P. Strassburg1 , T. Becker3 , H. Barg-Hock3 , M. Bastürk1 , K. Wursthorn1 , M. Cornberg1 , M. Ott1, 4 , T. F. Greten1 , M. P. Manns1 , H. Wedemeyer1
  • 1Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
  • 2Department of Cardiology, Medical School Hannover, Hannover, Germany
  • 3Department of Visceral and Transplant Surgery, Medical School Hannover, Hannover, Germany
  • 4Twincore Center for Experimental and Clinical Infection Research, Hannover, Germany
Further Information

Publication History

manuscript received: 26.2.2009

manuscript accepted: 31.8.2009

Publication Date:
02 February 2010 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Reaktivierung einer Hepatitis-B-Virus-Infektion während immunsuppressiver Therapien kann zu akutem Leberversagen führen, für welches es nur begrenzt Therapieoptionen gibt. In der vorliegenden Fallbeschreibung werden 2 Fälle präsentiert mit schwerer Hepatitis-B-Reaktivierung unter immunsuppressiver Therapie mit Rituximab bei B-Zell-Lymphom, die mit Leber- bzw. Leberzelltransplantation behandelt wurden. Vor Beginn der immunsuppressiven Therapie war die Leberfunktion normal und eine Hepatitis-B-Infektion unbekannt. Nach 4 bzw. 6 Zyklen Chemotherapie wurde erstmalig eine eingeschränkte Leberfunktion festgestellt und im Verlauf entwickelte sich bei beiden Patienten ein akutes Leberversagen trotz antiviraler Therapie mit Lamivudin oder Entecavir. Patient A wurde bei kompletter Remission des B-Zell-Lymphoms lebertransplantiert und überlebte bisher ohne Zeichen einer Hepatitis-B-Reaktivierung. Patient B erhielt 4 Zyklen einer Leberzell-Transplantation, überlebte allerdings nicht. Diese Fälle verdeutlichen die Relevanz von anti-HBc-Screeninguntersuchungen bei Patienten mit immunsuppressiver Therapie, insbesondere mit Rituximab. Eine prophylaktische antivirale Behandlung ist indiziert, da ein später Beginn der antiviralen Therapie ein Leberversagen häufig nicht mehr verhindern kann.

Abstract

Hepatitis B virus reactivation during immunosuppressive therapies can lead to liver failure with very limited treatment options available. We report here on two cases of severe hepatitis B reactivation during chemotherapy including rituximab for B cell lymphoma which were treated with liver or liver-cell transplantation. Liver function was normal and HBV infection was unknown in both patients before chemotherapy was started. Impaired liver function became apparent after 4 and 6 courses of chemotherapy, respectively, and both patients experienced fulminant hepatic failure despite antiviral treatment with lamivudine or entecavir. Patient A underwent liver transplantation after documentation of complete remission of the lymphoma and survived without any evidence for hepatitis B recurrence. Patient B received 4 courses of hepatocyte transplantation but did not survive. These cases underline the importance of anti-HBc screening in patients receiving immunosuppressive treatments in particular when rituximab is given. Pre-emptive antiviral treatments should be administered since delayed antiviral treatment is frequently unable to prevent liver failure.

Schlüsselwörter

Rituximab - Hepatitis B - immunsuppressiver Therapie - Transplantation

Key words

rituximab - immunosuppression - hepatitis B - transplantation

References

  • 1 European Association for the Study of the Liver . EASL Clinical Practice Guidelines: Management of chronic hepatitis B.  J Hepatol. 2009;  50 in press
    Google Scholar
  • 2 Lok A S, McMahon B J. Chronic hepatitis B.  Hepatology. 2007;  45 507-539
    Google Scholar
  • 3 Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy.  J Hepatol. 2008;  48 (Suppl 1) S2-S19
    Google Scholar
  • 4 Raimondo G, Pollicino T, Cacciola I. et al . Occult hepatitis B virus infection.  J Hepatol. 2007;  46 160-170
    Google Scholar
  • 5 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection.  Nat Rev Immunol. 2005;  5 215-229
    Google Scholar
  • 6 Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.  Br J Haematol. 2007;  136 699-712
    Google Scholar
  • 7 Yeo W, Johnson P J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.  Hepatology. 2006;  43 209-220
    Google Scholar
  • 8 Yeo W, Zee B, Zhong S. et al . Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.  Br J Cancer. 2004;  90 1306-1311
    Google Scholar
  • 9 Cornberg M, Protzer U, Dollinger M M. et al . Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.  Z Gastroenterol. 2007;  45 1281-1328
    Google Scholar
  • 10 Rosenau J, Kreutz T, Kujawa M. et al . HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.  J Hepatol. 2007;  46 635-644
    Google Scholar
  • 11 Schneider A, Attaran M, Meier P N. et al . Hepatocyte transplantation in an acute liver failure due to mushroom poisoning.  Transplantation. 2006;  82 1115-1116
    Google Scholar
  • 12 Alexandrova K, Griesel C, Barthold M. et al . Large-scale isolation of human hepatocytes for therapeutic application.  Cell Transplant. 2005;  14 845-853
    Google Scholar
  • 13 Coiffier B, Lepage E, Briere J. et al . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.  N Engl J Med. 2002;  346 235-242
    Google Scholar
  • 14 Hui C K, Cheung W W, Zhang H Y. et al . Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.  Gastroenterology. 2006;  131 59-68
    Google Scholar
  • 15 Rehermann B, Ferrari C, Pasquinelli C. et al . The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.  Nat Med. 1996;  2 1104-1108
    Google Scholar
  • 16 Menne S, Cote P J, Butler S D. et al . Immunosuppression reactivates viral replication long after resolution of woodchuck hepatitis virus infection.  Hepatology. 2007;  45 614-622
    Google Scholar
  • 17 Ciesek S, Helfritz F A, Lehmann U. et al . Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver.  J Infect Dis. 2008;  197 355-360
    Google Scholar
  • 18 Cahalan M D, Parker I. Close encounters of the first and second kind: T-DC and T-B interactions in the lymph node.  Semin Immunol. 2005;  17 442-451
    Google Scholar
  • 19 Tillmann H L, Hadem J, Leifeld L. et al . Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.  J Viral Hepat. 2006;  13 256-263
    Google Scholar
  • 20 ter Borg F, Smorenburg S, Man R A. et al . Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.  Dig Dis Sci. 1998;  43 2267-2270
    Google Scholar
  • 21 Clark F L, Drummond M W, Chambers de S. et al . Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin’s lymphoma.  Ann Oncol. 1998;  9 385-387
    Google Scholar
  • 22 Santantonio T, Mazzola M, Pastore G. Lamivudine is safe and effective in fulminant viral hepatitis.  J Hepatol. 1999;  30 551
    Google Scholar
  • 23 Girke J, Wedemeyer H, Wiegand J. et al . Acute hepatitis B: is antiviral therapy indicated? Two case reports.  Dtsch Med Wochenschr. 2008;  133 1178-1182
    Google Scholar
  • 24 Raimondo G, Pollicino T, Cacciola I. et al . Occult hepatitis B virus infection.  J Hepatol. 2007;  46 160-170
    Google Scholar
  • 25 Li Y H, He Y F, Jiang W Q. et al . Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.  Cancer. 2006;  106 1320-1325
    Google Scholar
  • 26 Lau G K, Yiu H H, Fong D Y. et al . Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.  Gastroenterology. 2003;  125 1742-1749
    Google Scholar
  • 27 Shibolet O, Ilan Y, Gillis S. et al . Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.  Blood. 2002;  100 391-396
    Google Scholar
  • 28 Martyak L A, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis.  Liver Int. 2008;  28 28-38
    Google Scholar
  • 29 Katz L H, Fraser A, Gafter-Gvili A. et al . Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.  J Viral Hepat. 2008;  15 89-102
    Google Scholar
  • 30 Loomba R, Rowley A, Wesley R. et al . Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.  Ann Intern Med. 2008;  148 519-528
    Google Scholar
  • 31 Lai C L, Shouval D, Lok A S. et al . Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.  N Engl J Med. 2006;  354 1011-1020
    Google Scholar
  • 32 Ott M. A symphony of techniques for liver cell therapy, only applicable to rats?.  J Hepatol. 2008;  49 6-8
    Google Scholar
  • 33 Tsutsumi Y, Tanaka J, Kawamura T. et al . Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma.  Ann Hematol. 2004;  83 58-60
    Google Scholar
  • 34 Tsutsumi Y, Kawamura T, Saitoh S. et al . Hepatitis B virus reactivation in a case of non-Hodgkin’s lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.  Leuk Lymphoma. 2004;  45 627-629
    Google Scholar
  • 35 Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab.  N Engl J Med. 2001;  344 68-69
    Google Scholar
  • 36 Westhoff T H, Jochimsen F, Schmittel A. et al . Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.  Blood. 2003;  102 1930
    Google Scholar
  • 37 Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb.  J Infect Chemother. 2005;  11 189-191
    Google Scholar
  • 38 Law J K, Ho J K, Hoskins P J. et al . Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.  Leuk Lymphoma. 2005;  46 1085-1089
    Google Scholar
  • 39 Sera T, Hiasa Y, Michitaka K. et al . Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab.  Intern Med. 2006;  45 721-724
    Google Scholar
  • 40 Perceau G, Diris N, Estines O. et al . Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.  Br J Dermatol. 2006;  155 1053-1056
    Google Scholar
  • 41 Ono K, Iyama S, Matsunaga T. et al . Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma.  Gan To Kagaku Ryoho. 2007;  34 1509-1512
    Google Scholar
  • 42 Lovric S, Erdbruegger U, Kümpers P. et al . Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: single centre experience with 15 patients.  Nephrol Dial Transplant. 2009;  24 179-185
    Google Scholar
  • 43 Hernández J A, Diloy R, Salat D. et al . Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.  Haematologica. 2003;  88 ECR22
    Google Scholar
  • 44 Czuczman M S, Grillo-López A J, White C A. et al . Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.  J Clin Oncol. 1999;  17 268-276
    Google Scholar
  • 45 Ng H J, Lim L C. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report.  Ann Hematol. 2001;  80 549-552
    Google Scholar
  • 46 Skrabs C, Müller C, Agis H. et al . Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge.  Leukemia. 2002;  16 1884-1886
    Google Scholar

PD Dr. Heiner Wedemeyer

Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

Carl-Neuberg Str. 1

30625 Hannover

Germany

Phone: ++ 49/5 11/5 32 68 14

Fax: ++ 49/5 11/5 32 86 62

Email: stange.michelle@gmail.com

      >